Marinomed Biotech AG
MARI.VI · VIE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €0 | €0 | €0 | €0 |
| % Growth | -48.3% | -18.6% | -3% | – |
| Cost of Goods Sold | €0 | €0 | €0 | €0 |
| Gross Profit | -€0 | €0 | €0 | €0 |
| % Margin | -89.9% | 12.4% | 19% | 12.2% |
| R&D Expenses | €0 | €0 | €0 | €0 |
| G&A Expenses | €0 | €0 | €0 | €0 |
| SG&A Expenses | €0 | €0 | €0 | €0 |
| Sales & Mktg Exp. | €0 | €0 | €0 | €0 |
| Other Operating Expenses | -€0 | €0 | -€0 | -€0 |
| Operating Expenses | €0 | €0 | €0 | €0 |
| Operating Income | -€0 | -€0 | -€0 | -€0 |
| % Margin | -147.9% | -55.9% | -51% | -35.6% |
| Other Income/Exp. Net | -€0 | -€0 | -€0 | -€0 |
| Pre-Tax Income | -€0 | -€0 | -€0 | -€0 |
| Tax Expense | -€0 | €0 | €0 | €0 |
| Net Income | -€0 | -€0 | -€0 | -€0 |
| % Margin | -324.8% | -74% | -56.7% | -50.7% |
| EPS | -8.67 | -4.48 | -4.27 | -3.99 |
| % Growth | -93.5% | -4.9% | -7% | – |
| EPS Diluted | -8.67 | -4.5 | -4.27 | -3.99 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | €0 | €0 | €0 | -€0 |
| Interest Expense | €0 | €0 | €0 | €0 |
| Depreciation & Amortization | €0 | €0 | €0 | €0 |
| EBITDA | -€0 | -€0 | -€0 | -€0 |
| % Margin | -151.3% | -39.4% | -28.5% | -30.8% |